This study is looking into a new experimental drug called (2R,6R)-hydroxynorketamine (HNK) to see if it can help reduce short-term pain in healthy adults. Opioid pain medications can be addictive, and researchers are searching for new options. HNK is related to ketamine and may offer pain relief with fewer side effects. You might be able to join if you are a healthy adult between 18 and 60 years old. The main goal is to see if a single dose of HNK can reduce pain during special tests. This study aims to understand if HNK has pain-relieving effects and how it works in the brain, which could lead to new pain treatments.

Study design

This is a randomized, double-blind (you and your doctor won't know if you're getting the drug or placebo), placebo-controlled study involving 92 healthy volunteers.

What's involved

You will receive a single intravenous (IV) infusion of either HNK or a placebo over about 40 minutes. You will have inpatient and outpatient visits.

Compensation

Not stated in the trial record.

Follow-up

Pain ratings will be measured at 3-5 hours after the infusion, and secondary outcomes will be assessed immediately after infusion, after 4-5 hours, and one day later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.